Anaerobic antimicrobial therapy after necrotizing enterocolitis in VLBW infants

To evaluate the effect of anaerobic antimicrobial therapy for necrotizing enterocolitis (NEC) on clinical outcomes in very low birth weight (≤1500 g) infants. We identified very low birth weight infants with NEC from 348 US NICUs from 1997 to 2012. Anaerobic antimicrobial therapy was defined by anti...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatrics (Evanston) 2015-01, Vol.135 (1), p.e117-e125
Hauptverfasser: Autmizguine, Julie, Hornik, Christoph P, Benjamin, Jr, Daniel K, Laughon, Matthew M, Clark, Reese H, Cotten, C Michael, Cohen-Wolkowiez, Michael, Benjamin, Daniel K, Smith, P Brian
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e125
container_issue 1
container_start_page e117
container_title Pediatrics (Evanston)
container_volume 135
creator Autmizguine, Julie
Hornik, Christoph P
Benjamin, Jr, Daniel K
Laughon, Matthew M
Clark, Reese H
Cotten, C Michael
Cohen-Wolkowiez, Michael
Benjamin, Daniel K
Smith, P Brian
description To evaluate the effect of anaerobic antimicrobial therapy for necrotizing enterocolitis (NEC) on clinical outcomes in very low birth weight (≤1500 g) infants. We identified very low birth weight infants with NEC from 348 US NICUs from 1997 to 2012. Anaerobic antimicrobial therapy was defined by antibiotic exposure on the first day of NEC. We matched (1:1) infants exposed to anaerobic antimicrobial therapy with infants who were not exposed by using a propensity score stratified by NEC severity (medical and surgical). The primary composite outcome was in-hospital death or intestinal stricture. We assessed the relationship between anaerobic antimicrobial therapy and outcome by using a conditional logistic regression on the matched cohort. A total of 1390 infants exposed to anaerobic antimicrobial therapy were matched with 1390 infants not exposed. Mean gestational age and birth weight were 27 weeks and 946 g, respectively, and were similar in both groups. We found no significant difference in the combined outcome of death or strictures, but strictures as a single outcome were more common in the anaerobic antimicrobial therapy group (odds ratio 1.73; 95% confidence interval, 1.11-2.72). Among infants with surgical NEC, mortality was less common with anaerobic antimicrobial therapy (odds ratio 0.71; 95% confidence interval, 0.52-0.95). Anaerobic antimicrobial therapy was not associated with the composite outcome of death or strictures but was associated with an increase in intestinal strictures. This higher incidence of intestinal strictures may be explained by the fact that death is a competing outcome for intestinal strictures, and mortality was slightly lower in the anaerobic cohort. Infants with surgical NEC who received anaerobic antimicrobial therapy had lower mortality.
doi_str_mv 10.1542/peds.2014-2141
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4279070</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A401999444</galeid><sourcerecordid>A401999444</sourcerecordid><originalsourceid>FETCH-LOGICAL-c489t-b390b99ddb22a58d95af53ad1ba5683915de21a3bbbbba260b6f77cd031cb5743</originalsourceid><addsrcrecordid>eNqNkk1vGyEQhlHUKHGTXHOMVuoll3UGFpblUsmx0g_Jki9tc0TAsg7RGlxYV01_fUFOo7SnchkxPLyaeWcQusQwx4ySm53t05wApjXBFB-hGQbR1ZRw9gbNABpcUwB2it6m9AgAlHFygk4JYzgfPkPrhVc2Bu1Mpfzkts6Uixqr6cFGtXuq1DDZWHmb85P75fymsj5nggmjm1yqnK--rW7vcxyyQDpHx4Mak714jmfo64e7L8tP9Wr98fNysaoN7cRU60aAFqLvNSGKdb1gamCN6rFWrO0agVlvCVaNLkeRFnQ7cG763JDRjNPmDL0_6O72emt7k4uKapS76LYqPsmgnPz7xbsHuQk_ZLZGAIcscP0sEMP3vU2T3Lpk7Dgqb8M-SdwKKloOuP0PlOKOCUxYRt_9gz6GffTZiUIxzklLSvH1gdqo0UrnTciW_pyypaPdWJmNWq7lggIWQlBa-PmBz0NIKdrhpU8MsqyBLGsgyxrIsgb5w9Vrd17wP3NvfgN4oa5s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1645772624</pqid></control><display><type>article</type><title>Anaerobic antimicrobial therapy after necrotizing enterocolitis in VLBW infants</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Autmizguine, Julie ; Hornik, Christoph P ; Benjamin, Jr, Daniel K ; Laughon, Matthew M ; Clark, Reese H ; Cotten, C Michael ; Cohen-Wolkowiez, Michael ; Benjamin, Daniel K ; Smith, P Brian</creator><creatorcontrib>Autmizguine, Julie ; Hornik, Christoph P ; Benjamin, Jr, Daniel K ; Laughon, Matthew M ; Clark, Reese H ; Cotten, C Michael ; Cohen-Wolkowiez, Michael ; Benjamin, Daniel K ; Smith, P Brian ; Best Pharmaceuticals for Children Act—Pediatric Trials Network Administrative Core Committee</creatorcontrib><description>To evaluate the effect of anaerobic antimicrobial therapy for necrotizing enterocolitis (NEC) on clinical outcomes in very low birth weight (≤1500 g) infants. We identified very low birth weight infants with NEC from 348 US NICUs from 1997 to 2012. Anaerobic antimicrobial therapy was defined by antibiotic exposure on the first day of NEC. We matched (1:1) infants exposed to anaerobic antimicrobial therapy with infants who were not exposed by using a propensity score stratified by NEC severity (medical and surgical). The primary composite outcome was in-hospital death or intestinal stricture. We assessed the relationship between anaerobic antimicrobial therapy and outcome by using a conditional logistic regression on the matched cohort. A total of 1390 infants exposed to anaerobic antimicrobial therapy were matched with 1390 infants not exposed. Mean gestational age and birth weight were 27 weeks and 946 g, respectively, and were similar in both groups. We found no significant difference in the combined outcome of death or strictures, but strictures as a single outcome were more common in the anaerobic antimicrobial therapy group (odds ratio 1.73; 95% confidence interval, 1.11-2.72). Among infants with surgical NEC, mortality was less common with anaerobic antimicrobial therapy (odds ratio 0.71; 95% confidence interval, 0.52-0.95). Anaerobic antimicrobial therapy was not associated with the composite outcome of death or strictures but was associated with an increase in intestinal strictures. This higher incidence of intestinal strictures may be explained by the fact that death is a competing outcome for intestinal strictures, and mortality was slightly lower in the anaerobic cohort. Infants with surgical NEC who received anaerobic antimicrobial therapy had lower mortality.</description><identifier>ISSN: 0031-4005</identifier><identifier>ISSN: 1098-4275</identifier><identifier>EISSN: 1098-4275</identifier><identifier>DOI: 10.1542/peds.2014-2141</identifier><identifier>PMID: 25511117</identifier><identifier>CODEN: PEDIAU</identifier><language>eng</language><publisher>United States: American Academy of Pediatrics</publisher><subject>Anti-infective agents ; Anti-Infective Agents - adverse effects ; Babies ; Bacteria, Anaerobic ; Bacterial Infections - drug therapy ; Birth weight ; Birth weight, Low ; Care and treatment ; Clinical outcomes ; Dosage and administration ; Enterocolitis, Necrotizing - drug therapy ; Enterocolitis, Necrotizing - microbiology ; Enterocolitis, Neonatal necrotizing ; Enterocolitis, Pseudomembranous ; Female ; Health aspects ; Humans ; Infant, Newborn ; Infant, Very Low Birth Weight ; Infants ; Intestinal Obstruction - chemically induced ; Intestinal Obstruction - epidemiology ; Low birth weight ; Male ; Mortality ; Necrotizing enterocolitis ; Pediatrics ; Regression analysis ; Risk factors ; Treatment Outcome</subject><ispartof>Pediatrics (Evanston), 2015-01, Vol.135 (1), p.e117-e125</ispartof><rights>Copyright © 2015 by the American Academy of Pediatrics.</rights><rights>Copyright American Academy of Pediatrics Jan 2015</rights><rights>Copyright © 2015 by the American Academy of Pediatrics 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c489t-b390b99ddb22a58d95af53ad1ba5683915de21a3bbbbba260b6f77cd031cb5743</citedby><cites>FETCH-LOGICAL-c489t-b390b99ddb22a58d95af53ad1ba5683915de21a3bbbbba260b6f77cd031cb5743</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25511117$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Autmizguine, Julie</creatorcontrib><creatorcontrib>Hornik, Christoph P</creatorcontrib><creatorcontrib>Benjamin, Jr, Daniel K</creatorcontrib><creatorcontrib>Laughon, Matthew M</creatorcontrib><creatorcontrib>Clark, Reese H</creatorcontrib><creatorcontrib>Cotten, C Michael</creatorcontrib><creatorcontrib>Cohen-Wolkowiez, Michael</creatorcontrib><creatorcontrib>Benjamin, Daniel K</creatorcontrib><creatorcontrib>Smith, P Brian</creatorcontrib><creatorcontrib>Best Pharmaceuticals for Children Act—Pediatric Trials Network Administrative Core Committee</creatorcontrib><title>Anaerobic antimicrobial therapy after necrotizing enterocolitis in VLBW infants</title><title>Pediatrics (Evanston)</title><addtitle>Pediatrics</addtitle><description>To evaluate the effect of anaerobic antimicrobial therapy for necrotizing enterocolitis (NEC) on clinical outcomes in very low birth weight (≤1500 g) infants. We identified very low birth weight infants with NEC from 348 US NICUs from 1997 to 2012. Anaerobic antimicrobial therapy was defined by antibiotic exposure on the first day of NEC. We matched (1:1) infants exposed to anaerobic antimicrobial therapy with infants who were not exposed by using a propensity score stratified by NEC severity (medical and surgical). The primary composite outcome was in-hospital death or intestinal stricture. We assessed the relationship between anaerobic antimicrobial therapy and outcome by using a conditional logistic regression on the matched cohort. A total of 1390 infants exposed to anaerobic antimicrobial therapy were matched with 1390 infants not exposed. Mean gestational age and birth weight were 27 weeks and 946 g, respectively, and were similar in both groups. We found no significant difference in the combined outcome of death or strictures, but strictures as a single outcome were more common in the anaerobic antimicrobial therapy group (odds ratio 1.73; 95% confidence interval, 1.11-2.72). Among infants with surgical NEC, mortality was less common with anaerobic antimicrobial therapy (odds ratio 0.71; 95% confidence interval, 0.52-0.95). Anaerobic antimicrobial therapy was not associated with the composite outcome of death or strictures but was associated with an increase in intestinal strictures. This higher incidence of intestinal strictures may be explained by the fact that death is a competing outcome for intestinal strictures, and mortality was slightly lower in the anaerobic cohort. Infants with surgical NEC who received anaerobic antimicrobial therapy had lower mortality.</description><subject>Anti-infective agents</subject><subject>Anti-Infective Agents - adverse effects</subject><subject>Babies</subject><subject>Bacteria, Anaerobic</subject><subject>Bacterial Infections - drug therapy</subject><subject>Birth weight</subject><subject>Birth weight, Low</subject><subject>Care and treatment</subject><subject>Clinical outcomes</subject><subject>Dosage and administration</subject><subject>Enterocolitis, Necrotizing - drug therapy</subject><subject>Enterocolitis, Necrotizing - microbiology</subject><subject>Enterocolitis, Neonatal necrotizing</subject><subject>Enterocolitis, Pseudomembranous</subject><subject>Female</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Infant, Newborn</subject><subject>Infant, Very Low Birth Weight</subject><subject>Infants</subject><subject>Intestinal Obstruction - chemically induced</subject><subject>Intestinal Obstruction - epidemiology</subject><subject>Low birth weight</subject><subject>Male</subject><subject>Mortality</subject><subject>Necrotizing enterocolitis</subject><subject>Pediatrics</subject><subject>Regression analysis</subject><subject>Risk factors</subject><subject>Treatment Outcome</subject><issn>0031-4005</issn><issn>1098-4275</issn><issn>1098-4275</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkk1vGyEQhlHUKHGTXHOMVuoll3UGFpblUsmx0g_Jki9tc0TAsg7RGlxYV01_fUFOo7SnchkxPLyaeWcQusQwx4ySm53t05wApjXBFB-hGQbR1ZRw9gbNABpcUwB2it6m9AgAlHFygk4JYzgfPkPrhVc2Bu1Mpfzkts6Uixqr6cFGtXuq1DDZWHmb85P75fymsj5nggmjm1yqnK--rW7vcxyyQDpHx4Mak714jmfo64e7L8tP9Wr98fNysaoN7cRU60aAFqLvNSGKdb1gamCN6rFWrO0agVlvCVaNLkeRFnQ7cG763JDRjNPmDL0_6O72emt7k4uKapS76LYqPsmgnPz7xbsHuQk_ZLZGAIcscP0sEMP3vU2T3Lpk7Dgqb8M-SdwKKloOuP0PlOKOCUxYRt_9gz6GffTZiUIxzklLSvH1gdqo0UrnTciW_pyypaPdWJmNWq7lggIWQlBa-PmBz0NIKdrhpU8MsqyBLGsgyxrIsgb5w9Vrd17wP3NvfgN4oa5s</recordid><startdate>201501</startdate><enddate>201501</enddate><creator>Autmizguine, Julie</creator><creator>Hornik, Christoph P</creator><creator>Benjamin, Jr, Daniel K</creator><creator>Laughon, Matthew M</creator><creator>Clark, Reese H</creator><creator>Cotten, C Michael</creator><creator>Cohen-Wolkowiez, Michael</creator><creator>Benjamin, Daniel K</creator><creator>Smith, P Brian</creator><general>American Academy of Pediatrics</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>U9A</scope><scope>7X8</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>201501</creationdate><title>Anaerobic antimicrobial therapy after necrotizing enterocolitis in VLBW infants</title><author>Autmizguine, Julie ; Hornik, Christoph P ; Benjamin, Jr, Daniel K ; Laughon, Matthew M ; Clark, Reese H ; Cotten, C Michael ; Cohen-Wolkowiez, Michael ; Benjamin, Daniel K ; Smith, P Brian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c489t-b390b99ddb22a58d95af53ad1ba5683915de21a3bbbbba260b6f77cd031cb5743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Anti-infective agents</topic><topic>Anti-Infective Agents - adverse effects</topic><topic>Babies</topic><topic>Bacteria, Anaerobic</topic><topic>Bacterial Infections - drug therapy</topic><topic>Birth weight</topic><topic>Birth weight, Low</topic><topic>Care and treatment</topic><topic>Clinical outcomes</topic><topic>Dosage and administration</topic><topic>Enterocolitis, Necrotizing - drug therapy</topic><topic>Enterocolitis, Necrotizing - microbiology</topic><topic>Enterocolitis, Neonatal necrotizing</topic><topic>Enterocolitis, Pseudomembranous</topic><topic>Female</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Infant, Newborn</topic><topic>Infant, Very Low Birth Weight</topic><topic>Infants</topic><topic>Intestinal Obstruction - chemically induced</topic><topic>Intestinal Obstruction - epidemiology</topic><topic>Low birth weight</topic><topic>Male</topic><topic>Mortality</topic><topic>Necrotizing enterocolitis</topic><topic>Pediatrics</topic><topic>Regression analysis</topic><topic>Risk factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Autmizguine, Julie</creatorcontrib><creatorcontrib>Hornik, Christoph P</creatorcontrib><creatorcontrib>Benjamin, Jr, Daniel K</creatorcontrib><creatorcontrib>Laughon, Matthew M</creatorcontrib><creatorcontrib>Clark, Reese H</creatorcontrib><creatorcontrib>Cotten, C Michael</creatorcontrib><creatorcontrib>Cohen-Wolkowiez, Michael</creatorcontrib><creatorcontrib>Benjamin, Daniel K</creatorcontrib><creatorcontrib>Smith, P Brian</creatorcontrib><creatorcontrib>Best Pharmaceuticals for Children Act—Pediatric Trials Network Administrative Core Committee</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pediatrics (Evanston)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Autmizguine, Julie</au><au>Hornik, Christoph P</au><au>Benjamin, Jr, Daniel K</au><au>Laughon, Matthew M</au><au>Clark, Reese H</au><au>Cotten, C Michael</au><au>Cohen-Wolkowiez, Michael</au><au>Benjamin, Daniel K</au><au>Smith, P Brian</au><aucorp>Best Pharmaceuticals for Children Act—Pediatric Trials Network Administrative Core Committee</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anaerobic antimicrobial therapy after necrotizing enterocolitis in VLBW infants</atitle><jtitle>Pediatrics (Evanston)</jtitle><addtitle>Pediatrics</addtitle><date>2015-01</date><risdate>2015</risdate><volume>135</volume><issue>1</issue><spage>e117</spage><epage>e125</epage><pages>e117-e125</pages><issn>0031-4005</issn><issn>1098-4275</issn><eissn>1098-4275</eissn><coden>PEDIAU</coden><abstract>To evaluate the effect of anaerobic antimicrobial therapy for necrotizing enterocolitis (NEC) on clinical outcomes in very low birth weight (≤1500 g) infants. We identified very low birth weight infants with NEC from 348 US NICUs from 1997 to 2012. Anaerobic antimicrobial therapy was defined by antibiotic exposure on the first day of NEC. We matched (1:1) infants exposed to anaerobic antimicrobial therapy with infants who were not exposed by using a propensity score stratified by NEC severity (medical and surgical). The primary composite outcome was in-hospital death or intestinal stricture. We assessed the relationship between anaerobic antimicrobial therapy and outcome by using a conditional logistic regression on the matched cohort. A total of 1390 infants exposed to anaerobic antimicrobial therapy were matched with 1390 infants not exposed. Mean gestational age and birth weight were 27 weeks and 946 g, respectively, and were similar in both groups. We found no significant difference in the combined outcome of death or strictures, but strictures as a single outcome were more common in the anaerobic antimicrobial therapy group (odds ratio 1.73; 95% confidence interval, 1.11-2.72). Among infants with surgical NEC, mortality was less common with anaerobic antimicrobial therapy (odds ratio 0.71; 95% confidence interval, 0.52-0.95). Anaerobic antimicrobial therapy was not associated with the composite outcome of death or strictures but was associated with an increase in intestinal strictures. This higher incidence of intestinal strictures may be explained by the fact that death is a competing outcome for intestinal strictures, and mortality was slightly lower in the anaerobic cohort. Infants with surgical NEC who received anaerobic antimicrobial therapy had lower mortality.</abstract><cop>United States</cop><pub>American Academy of Pediatrics</pub><pmid>25511117</pmid><doi>10.1542/peds.2014-2141</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0031-4005
ispartof Pediatrics (Evanston), 2015-01, Vol.135 (1), p.e117-e125
issn 0031-4005
1098-4275
1098-4275
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4279070
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Anti-infective agents
Anti-Infective Agents - adverse effects
Babies
Bacteria, Anaerobic
Bacterial Infections - drug therapy
Birth weight
Birth weight, Low
Care and treatment
Clinical outcomes
Dosage and administration
Enterocolitis, Necrotizing - drug therapy
Enterocolitis, Necrotizing - microbiology
Enterocolitis, Neonatal necrotizing
Enterocolitis, Pseudomembranous
Female
Health aspects
Humans
Infant, Newborn
Infant, Very Low Birth Weight
Infants
Intestinal Obstruction - chemically induced
Intestinal Obstruction - epidemiology
Low birth weight
Male
Mortality
Necrotizing enterocolitis
Pediatrics
Regression analysis
Risk factors
Treatment Outcome
title Anaerobic antimicrobial therapy after necrotizing enterocolitis in VLBW infants
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T00%3A27%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anaerobic%20antimicrobial%20therapy%20after%20necrotizing%20enterocolitis%20in%20VLBW%20infants&rft.jtitle=Pediatrics%20(Evanston)&rft.au=Autmizguine,%20Julie&rft.aucorp=Best%20Pharmaceuticals%20for%20Children%20Act%E2%80%94Pediatric%20Trials%20Network%20Administrative%20Core%20Committee&rft.date=2015-01&rft.volume=135&rft.issue=1&rft.spage=e117&rft.epage=e125&rft.pages=e117-e125&rft.issn=0031-4005&rft.eissn=1098-4275&rft.coden=PEDIAU&rft_id=info:doi/10.1542/peds.2014-2141&rft_dat=%3Cgale_pubme%3EA401999444%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1645772624&rft_id=info:pmid/25511117&rft_galeid=A401999444&rfr_iscdi=true